a phase ib trial of fixed-volume isatuximab infusion in newly-diagnosed multiple myeloma
Published 3 years ago • 13 plays • Length 3:28Download video MP4
Download video MP3
Similar videos
-
2:09
fixed-volume isatuximab infusion in newly-diagnosed myeloma
-
1:32
short-duration fixed-volume infusion of isatuximab in relapsed/refractory myeloma
-
2:25
results from a phase i/ii trial of pirtobrutinib and lv20.19 for patients with r/r lymphomas
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies
-
2:12
results from phase i study of alnuctamab administered intravenously & subcutaneously in r/r myeloma
-
4:04
the future of myeloma treatment and the possibility of cure
-
5:59
what is hrmm (high-risk multiple myeloma)?
-
7:18
response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
2:10
overview of a phase ii clinical trial of isatuximab
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:42
results from a phase i study of cc-98633 in r/r myeloma
-
1:40
utilizing ai for individualized treatment-adjusted risk stratification in newly diagnosed myeloma
-
3:45
update on phase i trial of teclistamab in r/r myeloma
-
2:17
extended follow-up of the master trial
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
2:52
induction therapy in newly diagnosed multiple myeloma
-
2:04
restarting the apoptotic pathway in myeloma cells
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
9:21
phase ib dose escalation trial of sar650984 improves outcomes in relapsed or refractory myeloma
-
2:17
moving towards fixed-duration treatment in multiple myeloma